BIOASTER and DA VOLTERRA signed a memorandum of understanding to initiate a research partnership based on the novel economic model of Technology Research Institute (TRIs).
The project, entitled DACCAR, (Destroy Antibiotics in Colon to Combat Antibiotic Resistance), aims to develop an innovative product limiting the emergence of multi-resistant bacteria in patients treated with antibiotics to protect the intestinal microbial flora from antibiotics side effects.
Thus, using a DACCAR product would result in minimizing nosocomial infections burden maintaining effectiveness of antibiotics (noteworthy carbapenems) reducing spread of antibiotic resistance.
DA VOLTERRA is a biotechnology company having a long and recognized expertise in the development of innovative products addressing the problem of antibiotic resistance by targeting the protection of the intestinal flora. This program is coming from earlier work done in the laboratory of Prof Antoine Andremont (AP-HP, Université Paris VII).
BIOASTER TRI has defined therapeutic strategies based on intestinal microbiota as one of its major research topics to combat infectious diseases. Learn more about BIOASTER TRI.